Keylight 1.2 for trial free#

(Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced six ePoster presentations on the BION-1301 and atrasentan clinical programs at ASN Kidney Week 2021. 04, 2021 (GLOBE NEWSWIRE) - Chinook Therapeutics, Inc. Chinook to host investor conference call and webcast today at 4:30 pm EDT with Jonathan Barratt, MChB, PhD, Mayer Professor of Renal Medicine at University of Leicester, and Laura Kooienga, MD, practicing nephrologist and Director of Research at Colorado Kidney Care.Additional data was presented on the atrasentan program, including translational research demonstrating ET A activation is associated with clinical progression inР’В IgAN.BION-1301 demonstrated >50% proteinuria reduction in patients with IgAN after three to six months of treatment, with further reductions in two patients through one year of treatment.

Keylight 1.2 for trial free#

BION-1301 was well-tolerated and demonstrated rapid and sustained reductions in mechanistic biomarkers in patients with IgAN, including free APRIL, IgA and Gd-IgA1 levels.